Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1

19 Mar 2020

Abstract excerpt

INTRODUCTION: To improve the standard treatment paradigm for glioblastoma (GBM), efforts have been made to explore the efficacy of epigenetic agents as chemosensitizers. Recent data suggest possible synergy between decitabine (DAC), a DNA hypomethylating agent, and temozolomide (TMZ) in GBM, but the mechanism remains unclear. The objective of this study was to determine the effects of DAC on TMZ sensitization in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32193690
DOI: 10.1007/s11060-020-03461-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1PMID 32193690Read ↗

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read ↗

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastomaSemantic proximity Read ↗

DNA Damage Response in GlioblastomaSemantic proximity Read ↗

Epigenetic Targeting of GlioblastomaSemantic proximity Read ↗

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapySemantic proximity Read ↗

Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastomaSemantic proximity Read ↗

The DNA methylome of glioblastoma multiforme.Semantic proximity Read ↗

TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.Semantic proximity Read ↗

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastomaSemantic proximity Read ↗

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in GlioblastomaSemantic proximity Read ↗

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.Semantic proximity Read ↗

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.